Rituxan is a biologic drug approved by the Food and Drug Administration (FDA) in 2006 to treat rheumatoid arthritis (RA). Its generic name is rituximab.

Following the categorization of rituximab timing, individuals with an infusion less than 4 months compared with greater than 8 months before COVID-19 onset had increased risk for hospitalization ...

Rituxan is given as an IV infusion and contains the active ingredient rituximab. Rituxan Hycela is available in two strengths: 1,400 mg of rituximab and 23,400 units of hyaluronidase human per 11. ...

Dr Le Gouill and colleagues concluded that rituximab maintenance (one infusion every 2 months for 3 years) ... Session chair Anca Prica, MD, from Princess Margaret Hospital, ...

The median time between the most recent rituximab infusion and COVID-19 onset was 6.1 months among patients with mild COVID-19 and 4.6 months among those who were hospitalized for COVID-19 (P = .16).

Patients with pemphigus in complete remission had a reduced risk of relapse after receiving an additional rituximab infusion at month 6, according to a study.In the RITUX 3 trial, patients with ...

Infusion-Related Reactions: Rituximab product administration can result in serious, including fatal, infusion-related reactions. Deaths within 24 hours of rituximab infusion have occurred.

Rituximab therapy was repeated in April 2002, after the mycophenolate and prednisolone treatment had been discontinued. Six weeks after the last infusion, the titer of anti–insulin-receptor ...

A total of 50 of the 54 patients in the rituximab group (92.6%) reported infusion-associated adverse events that were mild to moderate (grade 1 or 2) in severity.

2.2 Allergic and skin reactions are the most common adverse effects of rituximab infusion. Reactions during infusion can include bronchospasm and hypotension, which can be severe or life-threatening.

Rituximab was given at a dose of 375/m 2 intravenously (i.v.) on day 1 (D-1). Four mg of dexamethasone was given i.v. before the rituximab infusion, 4 mg i.v. halfway through and 4 mg of ...

Allergic and skin reactions are the most common adverse effects of rituximab infusion. Reactions during infusion can include bronchospasm and hypotension, which can be severe or life-threatening.